Patel Kinnari
Known title: See RemarksCIK: 0001725929
Patel Kinnari's purchase track record
Patel Kinnari has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/9/2025 | RCKT | $99K | -40.7% | -37.2% | +23.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 767 | $5K | 5/20/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,409 | $9K | 5/16/2025 | View on chart |
| RCKT | ▲ Buy | Open Market | 21,099 | $99K | 4/9/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 6,078 | $64K | 2/21/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 57,786 | $0 | 2/11/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 4,588 | $60K | 11/21/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,989 | $74K | 8/16/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 4,046 | $94K | 5/16/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 3,990 | $0 | 5/14/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 5,553 | $0 | 5/14/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 7,132 | $213K | 2/16/2024 | View on chart |
| RCKT | ▲ Buy | Grant | 33,288 | $0 | 2/16/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 26,189 | $0 | 2/14/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 3,989 | $0 | 11/14/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 3,333 | $0 | 10/5/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,534 | $24K | 8/17/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 3,989 | $0 | 8/14/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,330 | $28K | 5/17/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 3,989 | $0 | 5/14/2023 | View on chart |
| RCKT | ▼ Sell | Other | 38,735 | $0 | 2/14/2023 | View on chart |
| RCKT | ▼ Sell | Other | 52,489 | $0 | 8/12/2022 | View on chart |
| RCKT | ▼ Sell | Other | 11,970 | $0 | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.